What period on the daily chart do you set your CMF to, 30 or 50 days? I am a stockcharts member so already have been using this but you seem to know everything about this indicator. Thanks.
Correction: "and one competitor in the space RGRX". Junkdna50 has correctly pointed out that this symbol is wrong and should have been RGBP for Regen Biopharma traded on the OTC exchange and today closing at .23. ABOUT REGEN BIOPHARMA INC.: Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP) (OTC PINK: RGBP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space.
I am not recommending the stock, just cleaning up the quote in my post, my error.
We closed up the $.02 on total volume of 804,900 so we got 110,600 shares trade in the last two minutes (13.7% of day's volume) with many small trades going across at 2.93 until the close when the market maker puts a trade across of 66,900 at 2.92. That is the barrier 2.92 until we knock it down on volume.
Very low volume today 694,300 with two minutes to go, was looking at chart, seems there is resistance at 2.92 and we would require a move on volume to close above that level. Instead, volume is falling away with the price dropping into the close. A very good week, wanted to see it continue into a convincing higher close today, but alas, these stocks seldom do what you want when you want it. Good weekend to all longs.
Management said they would not be giving shareholders progressive update on enrollment. Anybody's guess until they release more information.
Hi lefty, hope you're right, seems that holding was the only option when I saw my equity almost cut in half, now that margin is cut down to minus 33.7% to get back to 2.17. I just couldn't bring myself to add more shares, having done that too many times at higher prices and then seeing all those shares in the red. So, it gets back to the one thing all biotech investors have to master, and that's having patience. I am in IDRA since March of 2014, and in that time I've seen my shares go down as low as 1.94, and recently 2.33, and as high #$%$24, now trading at 2.90. I expect that in Q4 IDRA shareholders will see $7 or more due to the coming spate of catalysts there. So, while adding there and in AVXL and TROV, I've left this position alone. Glad to see some life coming back into the share value, and also glad I held my shares for the ride back up. Good luck here and keep up the positive posting. Jr.
You must be really sadistic to try to push that theme on one man who happens to be very respected on this board, all those stocks you mention will be back up in several months if held, and you know it. You can't be so naive as to think one person's posting can affect the market for any stock. Sune traded 40 million shares today, IDRA traded 2.4 million, and TROV traded 558,000 shares. Back on ignore you go.
Yes, it was confusing thanks for helping to clear it up. Hope the article helps some here understand how gene silencing works, and maybe for some they have a new investment idea in a penny stock showing promise?
You are correct, no symbol was mentioned, but there are two companies with very similar names and different symbols. The one you mention and correct symbol for is RGBP. Thanks for persisting, I stand corrected. Their stock is up from .15 to .23 since this article hit the Internet.
Wouldn't the institutions who bought into the secondary have asked the kind of questions you are asking before they invested big into this company at $8.75? I like your skepticism in looking beyond the "giddy enthusiasm" that MGM refers to, and reading between the lines. I will give it a re-listen as you have now prompted me to look deeper.
On another note, as I had anticipated, the stock appears to have turned up today rather decisively. Looks like adding the previous two days was a good decision, my pps is now slightly over $8 so have a ways to go before my snorkel isn't needed any longer, but it's what I was looking for yesterday when I saw the stock do that intra-day reversal.
From the 10Q looks like their burn rate is 10.2 per quarter, so there's two years of cash runway before they need to raise cash. If they come out with good data, they might attract a partner or grant money in the meantime. Second day of gains in a row, looks like maybe the downtrend has been checked, now we can get up and run? We'll see, did you get in?
So, they have qualified his replacement already the PR says, but they didn't disclose who that person is or give his resume'. Wonder why they held that back?
OK, this is rehashing old news, today's 9 cent gain is more like it, finally somebody came to get invested here and drove the price up. 213,000 shares is small volume, so probably doesn't hold much significance, but it's a start.
"On August 17, 2015, Andrew Pecora, MD resigned as Chief Medical Officer of PCT, a Caladrius Company, LLC ("PCT"), effective as of September 1, 2015. Dr. Pecora is also a member of the Board of Directors of Caladrius Biosciences, Inc. (the "Company") and shall remain on the Company's Board notwithstanding his resignation as Chief Medical Officer of PCT, the Company's wholly owned subsidiary. Dr. Pecora's resignation follows the qualification of a full-time permanent employee phyisician at PCT to assume the role of Chief Medical Officer of PCT."
This is the PR, and they could have easily explained that Pecora was unable to attend fully to the CMO for PCT since he was a full time employed as Hematologist/Oncologist at Hackensack Medical Center. Such a simple oversight in basic communication, makes me doubt their experience in leading a company.
Why didn't the Company explain these circumstance in their PR, it would have made complete sense and waved off any misinterpretation in the marketplace by investors? They need to educate themselves on how to communicate with shareholders and the market. That ER conference call maybe gave them a dose of how poorly they constructed a report to shareholders, as the market dumped all over them the next week.
The above post is just an excerpt from the blog post. I subscribe to the blog so get articles emailed to me every week about immunology and advancing science to treat disease using stem cells, and now this shows up using Gene Silencing. Idera is leading in this area but not alone in the space as this article points out.
This article appears on the CIRM site, California Institute of Regenerative Medicine, and can be found by using search engines on the above title. It references great explanation of the science as explored by Academia and one competitor in the space, RGRX. There are many proposed strategies for killing cancer stem cells. Some of them center around overcoming life-extending features that CSCs have evolved including the ability to avoid normal cell death processes. One promising technology for targeting CSCs is gene silencing. This technique uses tools that turn off the expression of specific genes (hence the silencing) that are causing cancer cells to survive or divide.
Two independent groups recently announced positive results from studies that use gene silencing technology to kill breast and colon cancer stem cells. These two stories are a great example of how pre-clinical biology from academia can translate into clinical research in industry.
On the Academic Side
A group from Lausanne University Hospital in Switzerland reported in PloS One that silencing the expression of a gene called BORIS prevented the growth of breast and colon CSCs.
BORIS inhibits the function of an important tumor suppressor gene called CTCF. A tumor suppressor gene acts as a stop sign and prevents normal cells from turning into cancer cells. When tumor suppressors can’t do their normal job due to rogue jay-walkers like BORIS, normal cells lose an important line of defense and can turn into cancer cells. Typically, BORIS is only expressed in germ cells during development and not in adult cells in the body. However, scientists have found that BORIS is reactivated in some cancer cells, typically in CSCs.
The PLoS study confirmed that BORIS was reactivated in both breast and colon CSCs. One hallmark of CSCs is their ability to survive in 3D culture systems by forming sphere-like structures. They then asked whether silencing BORIS expression in breast and colon CSCs would prevent the formation of spheres in culture. They found that without BORIS, CSCs could no longer form spheres and survive in suspension. They went on to show that when BORIS is silenced, expression of stem cell and CSC genes was reduced in both the breast and colon CSCs. The authors concluded that BORIS is an important gene for CSC survival and “could be a potential new CSC biomarker that could be used as a therapeutic target for cancer therapy.”
BORIS is expressed in breast cancer stem cells (red) but not in breast cancer cells (blue).
BORIS is expressed in breast cancer stem cells (red) but not in breast cancer cells (blue). (Alberti et al. 2015)
On the Industry Side
Regen BioPharma reported on Monday that it successfully used gene silencing technology to kill colon CSCs by silencing BORIS expression. Their positive results have prompted the company to improve and advance its gene-silencing techniques so that it can file an IND (investigational new drug) application for the BORIS gene silencing technology. An IND with the Food and Drug Administration is the final step to beginning a clinical trial in humans.
Regen has published previously in this area and acknowledged the recent findings published in PLoS. In a press release, Thomas Ichim, CSO of Regen said:
From 2006-2008, together with a team of scientists from the Institute of Molecular Medicine and the National Institutes of Health, we published that vaccinating against BORIS results in immune response against and tumor regression in breast cancer, melanoma, and glioma. Subsequently, we published that gene silencing of BORIS can be utilized to selectively kill breast cancer cells. As we saw in the recent publication, the role of BORIS as an “Achilles Heel” of cancer is becoming more and more apparent. We are currently in the process of advancing our gene-silencing based approaches, in part by leveraging lessons we are learning during dCellVax development, in order to file an IND for BORIS gene silencing technology.
Thanks MGM for adding to the wealth of good posting here, keeping our next catalysts out in front of us. Like Stockof2013 said, we are coming into the time when our investment will shine and outperform, we've all paid our dues getting here, so let the good times roll. Since this week's "wild Monday" August 24th, when I added my most recent 4,000 shares of IDRA, it's been just as I would have scripted, steady gains day after day. Since then we've added $0.25/share, so a 10% gain so far this week with one day to go. The low that day was 2.27 and the closing price was 2.54 as compared to today's closing price of 2.89. I'm getting really excited to see what happens here in these last four months of 2015, and 2016-2017 should continue to get progressively more exciting for investors in Idera as Milano and Co. execute on the business plan, with everything being viewed within a five year context. How fast can we get from $3 to $8 a share? We have four months left in 2015, I think that's enough time, but most of it may come in November-December? We'll just have to wait and see. GLAL
Sentiment: Strong Buy
How does the Pepsi theory apply with today's 7.84% gain, did they just stop shorting today or was the chart and investment at $5.36 just too compelling as a value investment into a company with disruptive technology? I think his call for shares to drop further into the $4's was weak and posted three times last night that the stock had a strong chance to move up from there, rather than down. At least so far, that was correct. I believe we've seen the lows and investors' here watching missed the lows.
Matt, check out the little Yahoo 5-day chart to the right. That W bottom intraday with the stock closing at 5.36 is very positive. I added another 1,000 yesterday and the day before. RSI is near 30 and the MACD histogram went positive, slow stochastic is turning up, the daily looks better than the weekly. I think we'll be ok if we don't give up. Good luck!